Introduction SLE is a chronic autoimmune disease characterised by multisystem involvement and fluctuating clinical course, ...

Objective SLE affects multiple organs and is associated with increased mortality and organ damage. While treatment ...

Objective No studies have investigated the incidence and correlation of scarring and dyspigmentation across all cutaneous ...

Objective Negative self-perceptions of ageing are associated with decreased health-related quality of life (HRQoL) in older ...

Objective Glomerular immune complex deposition plays a central role in lupus nephritis (LN), but the prognostic relevance of individual immunoglobulin components remains unclear. This study aimed to ...

22 Historical aspects of B-cell depletion in SLE (8 October, 2025) ...

Belimumab (BEL) is a monoclonal antibody that selectively binds to BLyS, a survival factor for B cells, while anifrolumab (ANI) is a monoclonal antibody that binds to the type I interferon (IFN) ...

In 1998 Edwards and Cambridge from University College London became increasingly convinced that B-lymphocytes were critically involved in the development of rheumatoid arthritis. 1 For some people at ...

Cutaneous lupus erythematosus (CLE) has a large impact on quality of life (QoL). The goal of remission is important, but until recently has been difficult to achieve for many patients. There is now a ...

Background Litifilimab is a humanized IgG1 monoclonal antibody targeting BDCA2, a receptor predominantly expressed on plasmacytoid dendritic cells (pDCs). In Part A of the Phase 2 LILAC study ...

Systemic lupus erythematosus (SLE) is associated with a wide variety of ocular manifestations. Some of these include uveitis, occlusive retinal vasculitis, (epi)scleritis and keratitis. Uveitis is an ...

Background Systemic lupus erythematosus (SLE) often mimics the symptoms of other diseases, and the interval between symptom onset and diagnosis remains long in these patients. The aim of this study is ...